Short answer
Penumbra Inc (PEN) filed its Q3 2019 10-Q quarterly report on Nov 7, 2019 for the quarter ended Sep 30, 2019.
Penumbra Inc Q3 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $139.5M, up 24.8% YoY from $111.8M
- Gross margin 68.8% vs 67.1% YoY; operating margin 9.3% vs (18.6)%
- Best segment: Vascular revenue $56.3M, up 51.6%; worst: Neuro revenue $83.2M, up 11.5%
- Cash $111.6M vs $67.9M; marketable investments $82.9M vs $133.0M at December 31, 2018
- Nine-month operating cash flow $21.9M; capital expenditures $14.1M and continued investments in products, manufacturing and international expansion
Risk Factors
- No material changes or new risk factors identified since the December 31, 2018 Form 10-K
- Carried-forward risks not detailed in this 10-Q risk-factors section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.